Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purines | 7 | 2018 | 43 | 1.230 |
Why?
|
| Pyrazoles | 7 | 2018 | 61 | 1.200 |
Why?
|
| Myocardial Perfusion Imaging | 9 | 2018 | 71 | 1.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 7 | 2018 | 79 | 0.740 |
Why?
|
| Myocardial Ischemia | 3 | 2018 | 44 | 0.740 |
Why?
|
| Aminophylline | 1 | 2016 | 12 | 0.510 |
Why?
|
| Exercise Test | 8 | 2018 | 121 | 0.500 |
Why?
|
| Heart Rate | 3 | 2017 | 112 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 127 | 0.340 |
Why?
|
| Electrocardiography | 2 | 2018 | 97 | 0.260 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 119 | 0.250 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2015 | 13 | 0.240 |
Why?
|
| Vasodilator Agents | 4 | 2017 | 31 | 0.230 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 132 | 0.230 |
Why?
|
| Prognosis | 8 | 2018 | 808 | 0.220 |
Why?
|
| Middle Aged | 11 | 2021 | 9068 | 0.190 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 14 | 0.180 |
Why?
|
| Eating | 1 | 2021 | 57 | 0.180 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2018 | 15 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2017 | 36 | 0.160 |
Why?
|
| Male | 12 | 2021 | 14887 | 0.160 |
Why?
|
| Biomarkers | 2 | 2021 | 562 | 0.150 |
Why?
|
| Female | 11 | 2021 | 15334 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 11 | 0.140 |
Why?
|
| Double-Blind Method | 2 | 2016 | 408 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 324 | 0.140 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 132 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 67 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 68 | 0.140 |
Why?
|
| Aged | 7 | 2021 | 9119 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 20 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 12 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2018 | 1792 | 0.140 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2017 | 2 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2017 | 36 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2017 | 50 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 35 | 0.130 |
Why?
|
| Organophosphorus Compounds | 1 | 2016 | 5 | 0.130 |
Why?
|
| Organotechnetium Compounds | 1 | 2016 | 7 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 24 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 28 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 161 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 2 | 0.120 |
Why?
|
| Humans | 13 | 2021 | 27309 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 245 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 240 | 0.120 |
Why?
|
| Survival Rate | 4 | 2018 | 344 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1807 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 551 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2018 | 3551 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2017 | 631 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 675 | 0.080 |
Why?
|
| Incidence | 3 | 2015 | 763 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 478 | 0.060 |
Why?
|
| Risk Factors | 3 | 2017 | 2335 | 0.060 |
Why?
|
| Comorbidity | 2 | 2015 | 488 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 486 | 0.050 |
Why?
|
| United States | 2 | 2021 | 2078 | 0.050 |
Why?
|
| Chicago | 2 | 2015 | 953 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2021 | 29 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 58 | 0.050 |
Why?
|
| Diet | 1 | 2021 | 219 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 12 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 55 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3540 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 55 | 0.040 |
Why?
|
| Proteomics | 1 | 2018 | 89 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 140 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 179 | 0.030 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2016 | 7 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2016 | 7 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 172 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 353 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 127 | 0.030 |
Why?
|
| Echocardiography | 1 | 2016 | 74 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 350 | 0.030 |
Why?
|
| Heart Rate Determination | 1 | 2015 | 2 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 87 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 101 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 77 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 56 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 7946 | 0.030 |
Why?
|
| Child | 1 | 2016 | 1269 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 1444 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 2185 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 4841 | 0.020 |
Why?
|